Partner with ACS

Investing in Innovation.Building the Next Generation of Therapeutics.

ACS Biomed develops proprietary pharmaceutical and medical technologies focused on dermatology, ophthalmology and advanced medical devices, alongside a portfolio of six proprietary consumer health platforms — five commercialization-ready between Q4 2026 and Q1 2027, one in development. Our mission is to transform innovative research into globally commercialized healthcare solutions through scientific excellence, strategic partnerships and international development.

Company at a Glance

The pillars that define ACS Biomed — from intellectual property and commercial validation to clinical development and manufacturing strategy.

€16.5M
Estimated Total Development Budget
€10.6M
Contracted Minimum Purchase Obligations (5-Year LATAM Agreement)
10
Proprietary Assets & Platforms
1
ErpeCream Investigational Pharmaceutical Programme

The LATAM figure represents contracted minimum purchase obligations to be fulfilled over a five-year term, not revenue already collected or recognized.

Proprietary Technologies

Innovative therapeutic platforms protected by proprietary know-how and intellectual property.

Commercial Validation

International commercialization opportunities are assessed with qualified partners on a territory-specific basis; public agreement and registration details are not stated here without current documentary confirmation.

Clinical Development

Multiple development programs advancing through regulatory and clinical pathways.

Manufacturing Strategy

Industrial manufacturing scale-up supported by GMP production partners.

The Portfolio: 4 Assets

ACS Biomed holds 4 distinct proprietary assets: 2 commercial product families and 3 development programmes, with ErpeCream intentionally counted in both categories because its cosmetic product pathway and separate investigational pharmaceutical pathway are distinct uses of the same asset.

4
Total Assets
2
Commercial Products
3
Development Programs

ErpeCream®

Commercial ProductDevelopment Program

Cosmetic product family presented separately from the ErpeCream Investigational Pharmaceutical Development Programme; current clinical status and future regulatory milestones require confirmation.

ErpeLips™

Commercial Product

Cosmetic lip-care product family presented under the ErpeLips / E-Lip commercial identities; territory-specific availability and claims remain subject to applicable local requirements.

ACRO-EYE™

Development Program

Proprietary ophthalmic technology for ocular surface and dry eye disease, advancing through development toward its regulatory pathway.

Easy-Dialysis™

Development Program

Advanced medical device for dialysis, currently in industrial development toward CE certification.

The Consumer Health Platforms: 6 Platforms

Alongside the pharmaceutical pipeline, ACS Biomed has developed six proprietary consumer health platforms across joint, oral, women's and men's health. Five are commercialization-ready between Q4 2026 and Q1 2027; one — the next-generation oral gel platform — remains in development.

6
Total Platforms
5
Launch-Ready
4
Therapeutic Areas

ARTHOFLEX™

Launch-ready · Q4 2026

ACS Joint & Mobility

Functional topical platform for mobility and everyday comfort, segmented into three references by age band and lifestyle.

DENTAL-BIO™

Launch-ready · Q4 2026

ACS Oral Health

Oral-microbiome-oriented oral care platform, available as a paste, a chewable and a single-dose daily format.

ENERGYNE™

Launch-ready · Q1 2027

ACS Women's Health

Female vitality platform segmented by life stage, from age 25 through post-menopausal active ageing.

MACA PLUS™

Launch-ready · Q1 2027

ACS Men's Health

Multi-active platform for male vitality, with three references dedicated to energy, performance and active ageing.

ACS Women's Intimate Care

Launch-ready · Q1 2027

ACS Women's Health

Specialist system for female intimate wellbeing: the FloraDonna oral probiotic, VagiCream MenoBalance cream and the ACS Protect wash.

ADVANCED ORAL GEL PLATFORM

In development

ACS Oral Health

Next-generation oral gel platform with a dual formulation path — established ingredients and precision fermentation — currently in development.

Our Development Pipeline

Our proprietary technologies advance along a structured pathway, from research to global commercialization. The highlighted stage marks each program's current position.

ErpeCream®

Pharmaceutical Development · Recurrent Genital HSV

Separate investigational pharmaceutical development programme associated with ErpeCream; current study status, regulatory pathway and any future registration remain subject to documentary confirmation.

Research
Clinical Development
Phase IIb
Phase III
Global Licensing & Commercialization

ACRO-EYE™

Ophthalmology · Ocular surface

Proprietary ophthalmic technology for ocular surface and dry eye disease, advancing through development toward its regulatory pathway.

Technology Validation
Development
Regulatory Program
Commercialization

Easy-Dialysis™

Medical device · Nephrology

Advanced medical device designed to make dialysis simpler and safer, currently in industrial development toward CE certification.

Engineering
Prototype
Industrial Development
Market Entry

Why ACS Biomed

Scientific Innovation

Development of proprietary therapeutic technologies addressing significant unmet medical needs.

Commercial Strategy

International commercialization through licensing and exclusive distribution partnerships.

Long-Term Vision

Building an integrated pharmaceutical company with a scalable manufacturing network through qualified GMP partners and global commercial reach.

Investment Philosophy

Partnering for Long-Term Value Creation

ACS Biomed collaborates with strategic, institutional and qualified financial partners who share our long-term vision of developing innovative healthcare technologies. Our objective is to create sustainable value through disciplined clinical development, regulatory execution and international commercialization.

Participation Opportunities

Strategic Equity

For investors interested in participating in the long-term growth of ACS Biomed through equity participation.

Institutional & Strategic Partnerships

Designed for pharmaceutical companies, family offices and institutional investors interested in strategic collaborations, licensing opportunities or co-development initiatives.

Clinical Program Financing

Selected clinical development programs may be financed through individually negotiated financing agreements with qualified counterparties.

These arrangements are evaluated exclusively on a case-by-case basis following direct engagement and are not publicly offered.

Value Creation Strategy

Clinical Validation
Regulatory Progress
Commercial Partnerships
Global Commercialization
Long-Term Shareholder Value

Why Investors Engage With ACS Biomed

Proprietary technologies
International commercialization
Experienced management
Scalable manufacturing strategy
Global licensing potential
Long-term clinical development

Governance & Team

ACS Biomed is led by an experienced team and supported by a network of scientific advisors and high-level clinical and manufacturing partners.

Management Team

Led by experienced pharmaceutical and life-sciences executives overseeing corporate strategy, clinical development and commercialization.

Scientific & Advisory Board

Dermatology, virology and ophthalmology experts guiding research direction and clinical study design.

Clinical Partners

International CROs and qualified clinical sites executing our regulated studies.

Manufacturing Partners

GMP / ISO-certified production partners ensuring pharmaceutical-grade quality and industrial scalability.

Investor Relations

Speak with Our Investment Team

Qualified investors interested in learning more about ACS Biomed, our clinical development programs or potential strategic collaborations are invited to contact our Investor Relations team for confidential discussions.

The information provided on this page is intended solely for general corporate communication purposes and does not constitute a public offer of financial instruments, investment solicitation or investment advice. Any potential financing or investment opportunity is evaluated exclusively through individual discussions and, where applicable, formal contractual documentation in accordance with applicable laws and regulations.